查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1301005

生物等效性研究市场规模、份额和趋势分析报告：按分子类型（小分子、大分子）、配方、治疗领域、地区、细分市场趋势，2023-2030

Bioequivalence Studies Market Size, Share & Trends Analysis Report By Molecule Type (Small Molecule, Large Molecule), By Dosage Form, By Therapeutic Area, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 175 Pages | 商品交期: 2-10个工作天内

价格

生物等效性测试市场的增长和趋势

根据 Grand View Research, Inc. 的最新报告，预计 2023 年至 2030 年全球生物等效性研究市场将以 8.3% 的复合年增长率增长。到 2030 年将达到 12.722 亿美元。

罕见疾病研发活动的增加和仿製药需求的增加是推动生物等效性测试市场增长的主要因素。

生物等效性研究用于分析两种製剂的体内生物等效性。 如果两种药物是生物等效的，那么生物利用度和药代动力学 (PK) 参数预计在所有用途上都会得到同等反映。 该市场的主要参与者包括 ProRelix Services LLP、IQVIA、ICON plc、Charles River Laboratories、Labcorp Drug Development 等。

这些公司为参与药物开发的研究机构、製药公司和政府机构提供广泛的生物等效性和生物利用度服务。 由于肿瘤学、神经病学和免疫学等疾病领域旨在开发低成本生物仿製药和仿製药的临床研究活动的步伐不断加快，生物等效性研究预计也会加速，预计将促进市场发展。

过去几年，仿製药的市场投放率不断提高，对生物等效性研究产生了强劲的需求。 例如，美国食品药品监督管理局（FDA）宣布，截至2022年1月，美国FDA批准的生物类似药有33种，其中21种已上市。

COVID-19疫情对生物等效性测试市场产生了负面影响。 不过，为了缓解形势、恢復销售，一些企业采取了无机策略。 此外，俄罗斯和乌克兰之间的地缘政治战争导致整个生物等效性测试行业的销售额下降。 这对美国等某些经济体产生了重大影响，导致2022年整体市场收益小幅下降。

生物等效性测试市场报告亮点

  • 小分子细分市场在 2022 年的销售额中所占份额最大，达到 60.6%。 该细分市场是由对仿製药（主要是小分子）的需求稳步增长推动的。
  • 按剂型划分，固体口服剂型在 2022 年的销售额中所占份额最大，为 53.8%。 这是生产最佳质量口服固体剂型的另一项技术创新。
  • 预计肿瘤学在预测期内的复合年增长率为 8.7%。 这是由于市场上批准的癌症生物仿製药的比例不断增加。
  • 亚太地区预计在预测期内復合年增长率最高，达到 8.8%。 印度和中国等亚洲国家是仿製药的主要出口国，仿製药生产的蓬勃发展预计将增加对生物等效性研究的需求。

内容

第一章调查方法及范围

  • 市场细分和范围
    • 段范围
    • 区域范围
    • 估计/预测时间表
  • 调查方法
  • 信息获取
    • 购买的数据库
    • GVR 内部数据库
    • 次要信息
    • 初步调查
    • 初步调查的详细信息
  • 信息或数据分析
    • 数据分析模型
  • 市场形成和验证
  • 型号详细信息
    • 产品流分析（模型 1）
    • 批量价格分析（模型 2）
  • 辅助信息列表
  • 主要信息列表
  • 目的

第 2 章执行摘要

  • 市场前景
  • 分部展望
  • 竞争考虑因素

第三章市场变量、趋势和生物等效性研究范围

  • 市场体系展望
    • 母公司市场前景
    • 相关/补充市场前景
  • 市场动态
    • 市场驱动因素分析
    • 市场製约因素分析
    • 行业问题
  • 生物等效性研究：市场分析工具
    • 行业分析 - 搬运工
    • PESTEL 分析
    • 主要交易和战略联盟分析
    • 市场进入策略
    • COVID-19 感染的影响分析

第四章生物等效性测试市场：分子类型估计和趋势分析

  • 生物等效性测试市场：定义和范围
  • 生物等效性测试市场：2022 年和 2030 年分子类型市场份额分析
    • 小分子
    • 聚合物

第五章生物等效性测试市场：剂型估算和趋势分析

  • 生物等效性测试市场：定义和范围
  • 生物等效性测试市场：2022 年和 2030 年剂型市场份额分析
    • 固体口服剂型
    • 肠胃外製剂
    • 主题产品
    • 其他

第六章生物等效性测试市场：治疗领域预估及趋势分析

  • 生物等效性测试市场：定义和范围
  • 生物等效性测试市场：2022 年和 2030 年治疗领域市场份额分析
    • 肿瘤学
    • 神经病学
    • 代谢紊乱
    • 血液学
    • 免疫学
    • 骨科
    • 其他

第 7 章。生物等效性测试市场：阶段评估和趋势分析

  • 生物等效性测试市场：定义和范围
  • 生物等效性测试市场：2022 年和 2030 年分层市场份额分析
    • 药物发现
    • 临床前研究
    • 临床研究

第 8 章。生物等效性测试市场：区域估计和趋势分析

  • 2022 年和 2030 年区域市场份额分析
  • 2018-2030 年市场规模、预测、收入和趋势分析：
  • 北美
    • 2018-2030 年市场预估和预测（金钱）
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 意大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • MEA
    • 南非
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 科威特

第 9 章竞争格局

  • 2022 年公司市场份额分析
  • 公司简介
    • CliniExperts
    • ICBIO Corporation
    • ProRelix Services LLP
    • PPD, Inc
    • Syneos Health
    • Labcorp Drug Development
    • IQVIA
    • Charles River Laboratories Inc.
    • Icon PLC
    • Intertek Group plc
Product Code: GVR-4-68040-084-1

Bioequivalence Studies Market Growth & Trends

The global bioequivalence studies market size is expected to reach USD 1,272.2 million by 2030, expanding at a CAGR of 8.3% from 2023 to 2030, according to a new report by Grand View Research, Inc. The increasing R&D activities pertaining to rare diseases and growing demand for generics are the key factors driving the growth of the market for bioequivalence studies.

Bioequivalence studies are used to analyze the desired in vivo biological equivalence of two formulations of drug products. If two drugs are bioequivalent, then they would be anticipated to reflect equal rates of bioavailability and pharmacokinetic (PK) parameters for all intents and purposes. Some of the major players in the market include ProRelix Services LLP, IQVIA, ICON plc, Charles River Laboratories, and Labcorp Drug Development, among others.

These companies offer a wide range of bioequivalence and bioavailability services to research institutes, pharmaceutical companies, and government agencies involved in drug development. In addition, the increasing pace of clinical research activities with an aim to develop low-cost biosimilars and generics across disease areas such as cancer, neurology, immunology, etc., is anticipated to boost the market growth for bioequivalence studies.

The growing rate of generics launches has helped to create a significant demand for bioequivalence studies over the past few years. For instance, the U.S. Food and Drug Administration (FDA) announced that as of January 2022, there are 33 FDA-approved biosimilars in the U.S., among which 21 are commercially available in the market.

The COVID-19 pandemic negatively impacted the market for bioequivalence studies. However, several players adopted inorganic strategies to mitigate this situation and rebound their sales figures. Additionally, the geopolitical war between Russia and Ukraine has led to a drop in revenue across the bioequivalence industry, as clinical trials outsourced across the war-infected countries have been halted until further notice. This has greatly impacted certain economies, such as the U.S., due to which the overall market witnessed a moderate dip in its revenue during 2022.

Bioequivalence Studies Market Report Highlights

  • The small molecule segment accounted for the largest revenue share of 60.6% in 2022.The segment is driven by the steadily growing demand for generics, which constitute a vast portion of small molecules
  • Based on the dosage form, the solid oral dosage segment accounted for the largest revenue share of 53.8% in 2022, owing to innovations in the technology involved in manufacturing oral solids at an optimal quality
  • The oncology segment is anticipated to register the fastest CAGR of 8.7% during the forecast period. This is due to the growing rate of anti-cancer biosimilars being approved in the market
  • Asia Pacific is anticipated to witness the highest CAGR of 8.8% during the forecast timeframe. The expected high growth is primarily since Asian countries such as India and China are major exporters of generic drugs, which also suggests that they have a stronghold in the production of generic drugs, thereby supporting demand for bioequivalence studies

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Scope
    • 1.1.2. Regional scope
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
      • 1.3.5.1. Data for primary interviews in North America
      • 1.3.5.2. Data for primary interviews in Europe
      • 1.3.5.3. Data for primary interviews in Asia Pacific
      • 1.3.5.4. Data for primary interviews in Latin America
      • 1.3.5.5. Data for Primary interviews in MEA
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Bioequivalence Studies Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
    • 3.2.3. Industry challenges
  • 3.3. Bioequivalence Studies: Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Major Deals & Strategic Alliances Analysis
    • 3.3.4. Market Entry Strategies
    • 3.3.5. COVID-19 Impact Analysis

Chapter 4. Bioequivalence Studies Market: Molecule Type Estimates & Trend Analysis

  • 4.1. Bioequivalence Studies Market: Definition & Scope
  • 4.2. Bioequivalence Studies Market: Molecule Type Market Share Analysis, 2022 & 2030
    • 4.2.1. Small Molecule
      • 4.2.1.1. Small Molecule Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.2.2. Large Molecule
      • 4.2.2.1. Large Molecule Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Bioequivalence Studies Market: Dosage Form Estimates & Trend Analysis

  • 5.1. Bioequivalence Studies Market: Definition & Scope
  • 5.2. Bioequivalence Studies Market: Dosage Form Market Share Analysis, 2022 & 2030
    • 5.2.1. Solid Oral Dosage
      • 5.2.1.1. Solid Oral Dosage Market estimates and forecast 2018 to 2030 (USD Million)
    • 5.2.2. Parenteral Formulations
      • 5.2.2.1. Parenteral Formulations Market estimates and forecast 2018 to 2030 (USD Million)
    • 5.2.3. Topical Products
      • 5.2.3.1. Topical Products Market estimates and forecast 2018 to 2030 (USD Million)
    • 5.2.4. Others
      • 5.2.4.1. Others Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Bioequivalence Studies Market: Therapeutic Area Estimates & Trend Analysis

  • 6.1. Bioequivalence Studies Market: Definition & Scope
  • 6.2. Bioequivalence Studies Market: Therapeutic Area Market Share Analysis, 2022 & 2030
    • 6.2.1. Oncology
      • 6.2.1.1. Oncology market estimates and forecast 2018 to 2030 (USD Million)
    • 6.2.2. Neurology
      • 6.2.2.1. Neurology Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.2.3. Metabolic Disorders
      • 6.2.3.1. Metabolic Disorders Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.2.4. Hematology
      • 6.2.4.1. Hematology Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.2.5. Immunology
      • 6.2.5.1. Immunology Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.2.6. Orthopedics
      • 6.2.6.1. Orthopedics Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.2.7. Others
      • 6.2.7.1. Others Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Bioequivalence Studies Market: Phase Estimates & Trend Analysis

  • 7.1. Bioequivalence Studies Market: Definition & Scope
  • 7.2. Bioequivalence Studies Market: Phase Market Share Analysis, 2022 & 2030
    • 7.2.1. Drug Discover
      • 7.2.1.1. Drug Discover Market estimates and forecast 2018 to 2030 (USD Million)
    • 7.2.2. Preclinical Studies
      • 7.2.2.1. Preclinical Studies Market estimates and forecast 2018 to 2030 (USD Million)
    • 7.2.3. Clinical Studies
      • 7.2.3.1. Clinical Studies Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 8. Bioequivalence Studies Market: Regional Estimates & Trend Analysis

  • 8.1. Regional market share analysis, 2022 & 2030
  • 8.2. Market Size, & Forecasts, Revenue and Trend Analysis, 2018 to 2030:
  • 8.3. North America
    • 8.3.1. Market estimates and forecast, 2018 - 2030 (Value)
    • 8.3.2. U.S.
      • 8.3.2.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
    • 8.3.3. Canada
      • 8.3.3.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
  • 8.4. Europe
    • 8.4.1. U.K.
      • 8.4.1.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
    • 8.4.2. Germany
      • 8.4.2.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
    • 8.4.3. France
      • 8.4.3.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
    • 8.4.4. Italy
      • 8.4.4.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
    • 8.4.5. Spain
      • 8.4.5.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
    • 8.4.6. Denmark
      • 8.4.6.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
    • 8.4.7. Sweden
      • 8.4.7.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
    • 8.4.8. Norway
      • 8.4.8.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Market estimates and forecast, 2018 - 2030 (USD Billion, Volume, Thousand)
    • 8.5.2. China
      • 8.5.2.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
    • 8.5.3. India
      • 8.5.3.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
    • 8.5.4. Australia
      • 8.5.4.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
    • 8.5.5. Thailand
      • 8.5.5.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
    • 8.5.6. South Korea
      • 8.5.6.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
    • 8.6.2. Mexico
      • 8.6.2.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
    • 8.6.3. Argentina
      • 8.6.3.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
    • 8.7.3. UAE
      • 8.7.3.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
    • 8.7.4. Kuwait
      • 8.7.4.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)

Chapter 9. Competitive Landscape

  • 9.1. Company Market Share Analysis, 2022
  • 9.2. Company Profiles
    • 9.2.1. CliniExperts
      • 9.2.1.1. Company overview
      • 9.2.1.2. Financial Performance
      • 9.2.1.3. Product benchmarking
      • 9.2.1.4. Strategic initiatives
    • 9.2.2. ICBIO Corporation
      • 9.2.2.1. Company overview
      • 9.2.2.2. Financial performance
      • 9.2.2.3. Product benchmarking
      • 9.2.2.4. Strategic initiatives
    • 9.2.3. ProRelix Services LLP
      • 9.2.3.1. Company overview
      • 9.2.3.2. Financial performance
      • 9.2.3.3. Product benchmarking
      • 9.2.3.4. Strategic initiatives
    • 9.2.4. PPD, Inc
      • 9.2.4.1. Company overview
      • 9.2.4.2. Financial performance
      • 9.2.4.3. Product benchmarking
      • 9.2.4.4. Strategic initiatives
    • 9.2.5. Syneos Health
      • 9.2.5.1. Company overview
      • 9.2.5.2. Financial performance
      • 9.2.5.3. Product benchmarking
      • 9.2.5.4. Strategic initiatives
    • 9.2.6. Labcorp Drug Development
      • 9.2.6.1. Company overview
      • 9.2.6.2. Financial performance
      • 9.2.6.3. Product benchmarking
      • 9.2.6.4. Strategic initiatives
    • 9.2.7. IQVIA
      • 9.2.7.1. Company overview
      • 9.2.7.2. Financial performance
      • 9.2.7.3. Product benchmarking
      • 9.2.7.4. Strategic initiatives
    • 9.2.8. Charles River Laboratories Inc.
      • 9.2.8.1. Company overview
      • 9.2.8.2. Financial performance
      • 9.2.8.3. Product benchmarking
      • 9.2.8.4. Strategic initiatives
    • 9.2.9. Icon PLC
      • 9.2.9.1. Company overview
      • 9.2.9.2. Financial performance
      • 9.2.9.3. Product benchmarking
      • 9.2.9.4. Strategic initiatives
    • 9.2.10. Intertek Group plc
      • 9.2.10.1. Company overview
      • 9.2.10.2. Financial performance
      • 9.2.10.3. Product benchmarking
      • 9.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 North America Bioequivalence Studies market, by region, 2018 - 2030 (USD Million)
  • Table 4 North America Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 5 North America Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 6 North America Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 7 U.S. Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 8 U.S. Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 9 U.S. Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 10 Canada Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 11 Canada Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 12 Canada Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 13 Europe Bioequivalence Studies market, by region, 2018 - 2030 (USD Million)
  • Table 14 Europe Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 15 Europe Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 16 Europe Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 17 U.K. Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 18 U.K. Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 19 U.K. Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 20 Germany Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 21 Germany Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 22 Germany Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 23 France Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 24 France Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 25 France Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 26 Italy Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 27 Italy Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 28 Italy Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 29 Spain Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 30 Spain Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 31 Spain Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 32 Denmark Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 33 Denmark Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 34 Denmark Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 35 Sweden Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 36 Sweden Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 37 Sweden Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 38 Norway Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 39 Norway Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 40 Norway Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Bioequivalence Studies market, by region, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 45 China Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 46 China Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 47 China Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 48 Japan Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 49 Japan Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 50 Japan Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 51 India Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 52 India Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 53 India Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 54 Australia Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 55 Australia Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 56 Australia Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 57 South Korea Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 58 South Korea Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 59 South Korea Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 60 Thailand Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 61 Thailand Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 62 Thailand Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 63 Latin America Bioequivalence Studies market, by region, 2018 - 2030 (USD Million)
  • Table 64 Latin America Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 65 Latin America Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 66 Latin America Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 67 Brazil Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 68 Brazil Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 69 Brazil Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 70 Mexico Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 71 Mexico Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 72 Mexico Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 73 Argentina Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 74 Argentina Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 75 Argentina Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 76 Middle East and Africa Bioequivalence Studies market, by region, 2018 - 2030 (USD Million)
  • Table 77 Middle East and Africa Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 78 Middle East and Africa Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 79 Middle East and Africa Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 80 South Africa Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 81 South Africa Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 82 South Africa Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 86 UAE Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 87 UAE Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 88 UAE Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Bioequivalence Studies market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Bioequivalence Studies market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 91 Kuwait Bioequivalence Studies market, by Therapeutic Area, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modelling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Primary research pattern
  • Fig. 8 Primary interviews in North America
  • Fig. 9 Primary interviews in Europe
  • Fig. 10 Primary interviews in Asia Pacific
  • Fig. 11 Primary interviews in Latin America
  • Fig. 12 Primary interviews in MEA
  • Fig. 13 Market Snapshot
  • Fig. 14 Segment Snapshot
  • Fig. 15 Segment Snapshot
  • Fig. 16 Competitive Landscape Snapshot
  • Fig. 17 Bioequivalence Studies market segmentation
  • Fig. 18 Parent market outlook (2022)
  • Fig. 19 Related/ancillary market outlook (2022)
  • Fig. 20 Market driver relevance analysis (Current & future impact)
  • Fig. 21 Current shared services and outsourcing usage levels
  • Fig. 22 Market restraint relevance analysis (Current & future impact)
  • Fig. 23 Porter's five forces analysis
  • Fig. 24 SWOT analysis, by a factor (political & legal, economic and technological)
  • Fig. 25 Bioequivalence Studies Market Molecule Type outlook: Segment dashboard
  • Fig. 26 Bioequivalence Studies: Molecule Type movement analysis
  • Fig. 27 Small Molecule market, 2018 - 2030 (USD Million)
  • Fig. 28 Large Molecule market, 2018 - 2030 (USD Million)
  • Fig. 29 Bioequivalence Studies Market Dosage Form type outlook: Segment dashboard
  • Fig. 30 Bioequivalence Studies: Dosage Form movement analysis
  • Fig. 31 Solid Oral Dosage market, 2018 - 2030 (USD Million)
  • Fig. 32 Parenteral Formulations market, 2018 - 2030 (USD Million)
  • Fig. 33 Topical Products market, 2018 - 2030 (USD Million)
  • Fig. 34 Others market, 2018 - 2030 (USD Million)
  • Fig. 35 Bioequivalence Studies market Therapeutic Area outlook: Segment dashboard
  • Fig. 36 Bioequivalence Studies market: Therapeutic Area movement analysis
  • Fig. 37 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 38 Neurology market, 2018 - 2030 (USD Million)
  • Fig. 39 Metabolic Disorders market, 2018 - 2030 (USD Million)
  • Fig. 40 Hematology market, 2018 - 2030 (USD Million)
  • Fig. 41 Immunology market, 2018 - 2030 (USD Million)
  • Fig. 42 Others market, 2018 - 2030 (USD Million)
  • Fig. 43 Regional marketplace: Segment dashboard
  • Fig. 44 Regional outlook, 2022 & 2030
  • Fig. 45 North America market, 2018 - 2030 (USD Million)
  • Fig. 46 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 47 Canada market, 2018 - 2030 (USD Million)
  • Fig. 48 Europe market, 2018 - 2030 (USD Million)
  • Fig. 49 Germany market, 2018 - 2030 (USD Million)
  • Fig. 50 UK market, 2018 - 2030 (USD Million)
  • Fig. 51 France market, 2018 - 2030 (USD Million)
  • Fig. 52 Italy market, 2018 - 2030 (USD Million)
  • Fig. 53 Spain market, 2018 - 2030 (USD Million)
  • Fig. 54 Denmark market, 2018 - 2030(USD Million)
  • Fig. 55 Sweden market, 2018 - 2030 (USD Million)
  • Fig. 56 Norway market, 2018 - 2030 (USD Million)
  • Fig. 57 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 58 China market, 2018 - 2030 (USD Million)
  • Fig. 59 Japan market, 2018 - 2030 (USD Million)
  • Fig. 60 India market, 2018 - 2030 (USD Million)
  • Fig. 61 Australia market, 2018 - 2030 (USD Million)
  • Fig. 62 South Korea market, 2018 - 2030 (USD Million)
  • Fig. 63 Thailand market, 2018 - 2030 (USD Million)
  • Fig. 64 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 65 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 66 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 67 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 68 Middle East & Africa market, 2018 - 2030 (USD Million)
  • Fig. 69 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 70 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 71 UAE market, 2018 - 2030 (USD Million)
  • Fig. 72 Kuwait market, 2018 - 2030 (USD Million)